Agenix to Acquire Point-of-Care Diagnostic Technology From Tyrian Limited

Agenix Limited has announced an agreement with Tyrian Diagnostics Limited to license its rapid point-of-care human diagnostic technology in a share exchange transaction.

Under the terms of the agreement, Agenix will license exclusive world-wide royalty free rights to the human health application for Tyrian’s proprietary DiagnostIQ® rapid point-of-care test platform.

The DiagnostIQ® platform comprises a patented disposable test device which can be used for various applications either alone or together with the DiagnostIQ® Reader for various human, animal and agricultural applications to determine action to be taken at the point of care for human and veterinary tests or point of need for agricultural and environmental tests.

Agenix has licensed the rights to develop the DiagnostIQ® platform for human health applications and aims to develop the technology into a micro-array device so that it will process multiple human health diagnostic tests on the one system.

The device is currently licensed to Bayer CropScience AG for an agricultural application.

In an addition to the license, to be finalized in the near future, Agenix will also acquire a patent for Tyrian’s antibody-based test for active tuberculosis. This patent covers a novel biomarker, discovered by Tyrian, which has the potential to distinguish patients with active TB infection from those that have been infected in the past, or have been vaccinated.

Agenix Limited Chairman and Chief Executive Officer Nicholas Weston said, “This acquisition advances our product pipeline and adds to our human health diagnostics business. We now have a platform for human health array and micro-array technology developers globally, as well as a medical device product for our expanding China business.”